US Broker Ratings

Geron Corporation (GERN) Stock Analysis: A Biotech Play with a 167% Potential Upside

As investors turn their attention towards the healthcare sector, Geron Corporation (NASDAQ: GERN) stands out as a compelling opportunity within the biotechnology industry. With a robust market capitalization of $878.95..

Collegium Pharmaceutical (COLL) Stock Analysis: A Promising 25% Upside for Investors in Healthcare

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a prominent player in the healthcare sector, stands out with a robust potential upside of 25% according to recent analyst ratings. As a specialty pharmaceutical..

CareDx, Inc. (CDNA) Stock Analysis: Evaluating a 41.96% Potential Upside in the Healthcare Diagnostics Sector

CareDx, Inc. (NASDAQ: CDNA), a prominent player in the healthcare diagnostics and research industry, has recently caught the attention of investors, particularly due to its significant potential upside. With a..

Auna SA (AUNA) Stock Analysis: Evaluating a 98.9% Potential Upside in Healthcare Investments

Auna SA (AUNA), a healthcare service provider with operations in Mexico, Peru, and Colombia, stands out as a compelling opportunity for investors seeking exposure to the medical care facilities sector...

Cronos Group Inc. (CRON) Stock Analysis: Exploring a 5.05% Upside in the Cannabis Market

Cronos Group Inc. (NASDAQ: CRON), a notable player in the cannabinoid sector, is drawing investor attention with its potential upside of 5.05%, according to recent analyst ratings. As a company..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Exploring a Potential 75% Upside Amidst Industry Challenges

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is making waves in the biotechnology sector, drawing investor attention with its potential 75.17% upside based on current analyst ratings. As a key player..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: A Promising Biotech with 242.79% Potential Upside

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a dynamic player in the biotechnology industry, is positioning itself as a compelling opportunity in the healthcare sector. With its innovative pipeline targeting serious conditions..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: Uncovering a 166.3% Potential Upside in the Biotech Sector

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is making waves in the healthcare sector, specifically within biotechnology, by offering transformative immunology-based therapies. As a clinical-stage biopharmaceutical company, Zenas BioPharma focuses on leveraging..

Iovance Biotherapeutics (IOVA): Unpacking the 454% Upside Potential for Investors

In the rapidly evolving landscape of biotechnology, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stands out as a company with a promising future. With a market capitalization of $644.49 million, Iovance offers..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 227% Potential Upside in the Biotech Sector

Investors with a keen eye on the biotechnology sector may already be familiar with Taysha Gene Therapies, Inc. (TSHA). This Dallas-based biotech company is making waves with its ambitious pipeline..

Savara, Inc. (SVRA)

⚠️ No article content returned.

..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a 60% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is making waves in the biotechnology sector with its promising pipeline of treatments targeting neurodegenerative and endocrine conditions. As a clinical-stage pharmaceutical company based in..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking a 203% Potential Upside in the Biotech Sector

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a burgeoning player in the biotechnology sector, is catching the eye of investors with its promising pipeline and a staggering potential upside of 203.51%. Specializing..

REGENXBIO Inc. (RGNX): Investor Outlook Reveals 250% Upside Potential Amid Robust Pipeline

REGENXBIO Inc. (RGNX), a clinical-stage biotechnology company, could be a compelling opportunity for investors seeking exposure to the gene therapy sector. With a proprietary NAV Technology Platform, REGENXBIO is well-positioned..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 272% Potential Upside Amidst Biotech Innovations

Relay Therapeutics, Inc. (NASDAQ: RLAY) captures the attention of investors with its innovative approach to drug discovery, despite its volatile stock performance. With a market capitalization of $639.49 million, this..

Avanos Medical (AVNS) Stock Analysis: Navigating Challenges with Strategic Growth in Healthcare

Avanos Medical, Inc. (NYSE: AVNS) operates at the intersection of innovation and healthcare. Specializing in medical devices, Avanos is a key player in delivering solutions that enhance patient care. With..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Exploring a Potential 90% Upside for Investors

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stands out in the healthcare sector, operating within the drug manufacturers’ specialty and generic industry. With a market capitalization of $417.28 million, this Deer Park,..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 206.71% Potential Upside in Gene Editing

Intellia Therapeutics, Inc. (NASDAQ: NTLA) stands at the forefront of the biotech industry’s next big leap with its innovative gene editing technologies. As a clinical-stage company engaged in the development..

AbCellera Biologics Inc. (ABCL) Stock Analysis: A Promising 98% Upside in Biotech Innovation

For investors looking to tap into the burgeoning biotechnology sector, AbCellera Biologics Inc. (NASDAQ: ABCL) presents a compelling opportunity. Based in Vancouver, Canada, AbCellera is at the forefront of developing..

Neuropace, Inc. (NPCE) Stock Analysis: Eyeing a Promising 68% Upside in the Healthcare Sector

Neuropace, Inc. (NPCE), a pioneering entity in the healthcare sector, is capturing investor attention with its cutting-edge medical devices aimed at treating drug-resistant focal epilepsy. With a market capitalization of..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds